HC Wainwright Issues Positive Outlook for DWTX Earnings

Dogwood Therapeutics, Inc (NASDAQ:DWTX) – Analysts at HC Wainwright boosted their Q1 2026 earnings per share estimates for shares of Dogwood Therapeutics in a research note issued to investors on Thursday, March 19th. HC Wainwright analyst S. Lee now forecasts that the company will post earnings per share of ($0.30) for the quarter, up from their prior estimate of ($0.49). HC Wainwright has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Dogwood Therapeutics’ current full-year earnings is ($6.43) per share. HC Wainwright also issued estimates for Dogwood Therapeutics’ Q2 2026 earnings at ($0.32) EPS, Q3 2026 earnings at ($0.34) EPS, Q4 2026 earnings at ($0.37) EPS, FY2026 earnings at ($1.33) EPS, FY2027 earnings at ($1.62) EPS, FY2028 earnings at ($1.71) EPS and FY2029 earnings at $0.72 EPS.

Other equities analysts also recently issued reports about the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Dogwood Therapeutics in a research report on Monday, December 22nd. Wall Street Zen downgraded Dogwood Therapeutics to a “strong sell” rating in a report on Saturday, December 13th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $12.00.

Dogwood Therapeutics Stock Down 7.3%

DWTX stock opened at $2.78 on Monday. The stock has a market capitalization of $92.85 million, a price-to-earnings ratio of -0.15 and a beta of 1.90. Dogwood Therapeutics has a 52-week low of $2.60 and a 52-week high of $9.50. The stock’s fifty day simple moving average is $2.95 and its 200-day simple moving average is $4.64.

Dogwood Therapeutics (NASDAQ:DWTX) last released its earnings results on Wednesday, March 18th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.22) by $0.96.

Institutional Trading of Dogwood Therapeutics

A hedge fund recently bought a new stake in Dogwood Therapeutics stock. Marshall Wace LLP acquired a new stake in shares of Dogwood Therapeutics, Inc (NASDAQ:DWTX) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned about 0.51% of Dogwood Therapeutics at the end of the most recent reporting period. Institutional investors own 9.05% of the company’s stock.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.